๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for HER2 Negative

Use of Magtrace Bracketing for Excision of Lesion and Sentinel Lymph Node Localization in Breast Conserving Surgery for Breast Cancer NCT07844473NA1 site๐Ÿ“ Madinah King Faisal Specialist Hospital & Research Center ยท Tests: Super paramagnetic iron oxide bracketing injection Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer. NCT05378204NA25 sites๐Ÿ“ Bordeaux๐Ÿ“ Caen๐Ÿ“ Clermont-Ferrand Institut Claudius Regaud ยท Tests: Main study:, Sub-study: Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer NCT05430399Phase 32 sites๐Ÿ“ Guangzhou๐Ÿ“ Hunan Sun Yat-sen University ยท Tests: utidelone, docetaxel Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer NCT04090567Phase 21 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: Cediranib, Ceralasertib, Olaparib Step Count and Treatment Response in Neoadjuvant Breast Cancer NCT07162675n/a2 sites๐Ÿ“ Ankara๐Ÿ“ Ankara Ankara Etlik City Hospital ยท Tests: Huawei Fit 2 Smartwatch ABCSG 61 / TEODOR : Neoadjuvant TrEatment Optimization Driven by Circulating Tumor DNA and endOcrine Responsiveness NCT07084558NA14 sites๐Ÿ“ Vienna๐Ÿ“ Baden๐Ÿ“ Dornbirn Austrian Breast & Colorectal Cancer Study Group ยท Tests: blood sample for Signatera (TM) test, biopsy for Ki-67 assessment, FFPE tumor sample for Signatera (TM) test (archived) A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer NCT06678269Phase 17 sites๐Ÿ“ Basking Ridge๐Ÿ“ Middletown๐Ÿ“ Montvale Memorial Sloan Kettering Cancer Center ยท Tests: Abemaciclib, Radiation Therapy Efficacy of Supplement Adjuvant Capecitabine in HR+/HER2- Breast Cancer Patients With High Risks NCT05212454Phase 31 site๐Ÿ“ Hanzhou Second Affiliated Hospital, Zhejiang University, School of โ€ฆ ยท Tests: Capecitabine A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors NCT07318805Phase 113 sites๐Ÿ“ Duarte๐Ÿ“ Grand Rapids๐Ÿ“ Long Island City Pfizer ยท Tests: PF-08032562, Fulvestrant, Cetuximab, Fluorouracil, Oxaliplatin Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer NCT06179303Phase 23 sites๐Ÿ“ St Louis๐Ÿ“ Chapel Hill๐Ÿ“ Seattle University of Washington ยท Tests: Abemaciclib, Anastrozole, Biospecimen Collection, Computed Tomography, Diagnostic Imaging Testing DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs NCT06176261Phase 23 sites๐Ÿ“ Miami๐Ÿ“ Boston๐Ÿ“ Durham Nancy Lin, MD ยท Tests: Datopotamab Deruxtecan Study of AVZO-021 in Patients With Advanced Solid Tumors NCT05867251Phase 1, Phase 213 sites๐Ÿ“ New Haven๐Ÿ“ Sarasota๐Ÿ“ Tampa Avenzo Therapeutics, Inc. ยท Tests: AVZO-021, Palbociclib, Fulvestrant, Letrozole, Ribociclib Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer NCT05950945Phase 388 sites๐Ÿ“ Miami Beach๐Ÿ“ Tampa๐Ÿ“ Boston Daiichi Sankyo ยท Tests: Trastuzumab Deruxtecan Neoadjuvant Camrelizumab and Fluzoparib and Nab-paclitaxel in Early Breast Cancer With HRR Gene Mutation NCT05761470Phase 21 site๐Ÿ“ Guangzhou Ying Lin ยท Tests: Camrelizumab, Fluzoparib, Nab-paclitaxel A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer NCT07347600n/a32 sites๐Ÿ“ Xiamen๐Ÿ“ Lanzhou๐Ÿ“ Shijiazhuang Hoffmann-La Roche ยท Tests: Inavolisib, Palbociclib, Fulvestrant A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy NCT07071337Phase 32 sites๐Ÿ“ Beijing๐Ÿ“ Guangzhou Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ยท Tests: SKB264, Nab-paclitaxel, Paclitaxel, Capecitabine A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer NCT04985266Phase 249 sites๐Ÿ“ Angers๐Ÿ“ Annecy๐Ÿ“ Avignon Royal Marsden NHS Foundation Trust ยท Tests: Palbociclib 125Mg Tab, Fulvestrant injection, Tamoxifen, Letrozole, Exemestane Radiotherapy Followed by Chemotherapy Combined With Toripalimab in Local Advanced HR-positive,HER2-negative BC. NCT06705127Phase 21 site๐Ÿ“ Hangzhou First Affiliated Hospital of Zhejiang University ยท Tests: TORIPALIMAB INJECTION(JS001 ), Stereotactic Body Radiation Therapy (SBRT) Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer NCT05524584Phase 21 site๐Ÿ“ Orange University of California, Irvine ยท Tests: Fulvestrant, Anastrozole, Abemaciclib A Study of the TheraBionic P1 Device in Breast Cancer NCT07218432NA8 sites๐Ÿ“ Clarkston๐Ÿ“ Detroit๐Ÿ“ Farmington Hills Barbara Ann Karmanos Cancer Institute ยท Tests: TheraBionic P1 Device Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer NCT06220214EARLY Phase 11 site๐Ÿ“ Stony Brook Alison Stopeck ยท Tests: CEDM, CEDBT, Omnipaque 350mgI/mL Solution for Injection Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant With Neoadjuvant Therapy NCT05989347Phase 11 site๐Ÿ“ New Haven Yale University ยท Tests: Dapagliflozin 10mg Clinical Trial of Avasopasem in Patients With Metastatic Hormone Receptor Positive Breast Cancer With Progression on a CDK 4/6 Inhibitor and Hormonal Therapy NCT07137871Phase 11 site๐Ÿ“ San Antonio The University of Texas Health Science Center at San Antonio ยท Tests: Avasopasem Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors NCT07288359Phase 1, Phase 216 sites๐Ÿ“ Atlanta๐Ÿ“ Nashville๐Ÿ“ San Antonio Novartis Pharmaceuticals ยท Tests: GVV858, Fulvestrant, Letrozole Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer NCT06121570Phase 11 site๐Ÿ“ Guangzhou Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University ยท Tests: Sentinel Lymph Node Biopsy (SLNB), Doxorubicin, Epirubicin, Cyclophosphamide, Cyclophosphamide Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA NCT07070466Phase 22 sites๐Ÿ“ Santa Monica๐Ÿ“ Boston Massachusetts General Hospital ยท Tests: Ivonescimab, 5-Fluorouracil, Oxaliplatin, Leucovorin A Trial of HRS-6209-205 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-6209 in Combination Therapy in Subjects With HR-Positive/HER2-Negative Cancer NCT07358377Phase 16 sites๐Ÿ“ Bowral๐Ÿ“ Sydney๐Ÿ“ Sydney Atridia Pty Ltd. ยท Tests: HRS-6209 Capsules and fulvestrant injection Dalpiciclib Plus Toremifene for First-line Advanced HR Positive and HER2 Negative Breast Cancer NCT06495515Phase 21 site๐Ÿ“ Tianjin Tianjin Medical University Cancer Institute and Hospital ยท Tests: Dalpiciclib๏ผŒToremifen A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast Cancer NCT06508216Phase 1, Phase 21 site๐Ÿ“ Villejuif Gustave Roussy, Cancer Campus, Grand Paris ยท Tests: Dato-DXd, Durvalumab A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases NCT06764940Phase 212 sites๐Ÿ“ Duarte๐Ÿ“ Los Angeles๐Ÿ“ San Diego Biostar Pharma, Inc. ยท Tests: Utidelone, Utidelone in combination with capecitabine, Utidelone in combination with capecitabine, Utidelone in combinaโ€ฆ
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy